Dr. Gilda Melissa Portalatin, MD

Dr. Portalatin practices at Fresenius Kidney Care Lake Clarke Shores in West Palm Beach, Florida.

Dr. Portalatin's NPI, 1144781139, was assigned on March 31, 2019. Dr. Portalatin graduated from Ross University School of Medicine in 2019. Dr. Portalatin holds Florida license 167948.

Dr. Portalatin's primary practice is Fresenius Kidney Care Lake Clarke Shores, at 3047 Forest Hill Blvd, West Palm Beach, FL 33406 in Palm Beach County. The practice phone is (561) 641-9611.

Dr. Portalatin's primary practice is Fresenius Kidney Care Lake Clarke Shores in West Palm Beach, Florida. Dr. Portalatin is also affiliated with HCA Florida JFK Hospital. The medical group on file is Florida Kidney Physicians. Dmand AI also links Dr. Portalatin to 3 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Portalatin practices, 6 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Portalatin's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Portalatin is board certified in internal medicine by the American Board of Internal Medicine. Dr. Portalatin is licensed in Florida.

CMS data shows 583 Medicare services from Dr. Portalatin across 6 procedure codes in 2024, for 97 Medicare patients. Medicare paid $42,002 for them.

CMS counts 97 Medicare patients who saw Dr. Portalatin in 2024. The largest group is 75 to 84, with 38 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 25% are also on Medicaid. Their average risk score is 5.22, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Portalatin's median patient age at 74, with 47% women.

In 2024, Dr. Portalatin wrote 78 Medicare Part D claims for 26 patients. 69% of them were for generic drugs. CMS names the drug for 25 of them, across 2 drugs with 11 or more claims each, at $1,599 in total drug cost. In 2022, CMS named 11 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Portalatin for performance year 2024, reported as part of a group. Dr. Portalatin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Portalatin as offering telehealth.

Dmand AI links 11 papers to Dr. Portalatin, published from 2015 to 2025. 2022 was the busiest year, with 4. The most frequent topics are Signal Transduction, Antineoplastic Agents and Cell Line, Tumor. Dr. Portalatin's most frequent co-authors are Shane Anthony Bobart, MD, Surafel Kebede Gebreselassie, MD and Hong Liang, DO.

CMS Open Payments shows 20 general payments to Dr. Portalatin from 9 drug and device companies from 2020 to 2025. Food and beverage make up the largest share, 100% of the total. Inari Medical, Inc. paid the most, $193.

Dr. Portalatin graduated from Ross University School of Medicine in 2019.

Dr. Portalatin is in network with 14 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.